According to InvestingPro analysis, GSK maintains a "GREAT" financial health score, positioning it well for continued pharmaceutical innovation. If approved, depemokimab would be the first ultra ...

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

Key drugs Blenrep and Depemokimab show significant potential, with impressive Phase 3 results, expected to boost GSK's revenues by an extra £7 billion. Despite some IRA and clinical trial risks ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab in two respiratory indications – asthma with type II inflammation ...

https://www.tipranks.com/news/the-fly/gsk-shares-shorted-by-leading-u-s-hedge-fund-the-times-reports GSK (GSK) announced that the European Medicines Agency, EMA, has ...

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use of depemokimab in two indications. The submitted ...

GSK plc (LSE/NYSE: LON:GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug ...